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ABSTRACT 
Melanocortins (MCs) play an important role in feeding, metabolism, and energy expenditure. 
While melanocortin receptor (MCR) mRNA has been found in the mesolimbic dopamine (DA) 
pathway, the ability of melanocortins to regulate feeding and other behaviors through actions on 
the mesolimbic DA system have not been examined. Short-hairpin RNAs (shRNAs) were 
created targeting MC3R and MC4R and were tested via in vitro studies for their ability to 
knockdown their target receptor. A total of three shRNAs were created targeting each receptor, 
and each shRNA caused successful knockdown. These shRNAs are tools that can be used for 
future in vivo studies to examine the various behavioral effects of melanocortins on the 
mesolimbic DA pathway. 
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1 INTRODUCTION  
Today, it is estimated that 68% of adults and 32% of children in the United States are 
considered overweight or obese (Ogden et al 2012a; 2012b; Flegal et al 2010). Obesity is shown 
to have correlations with heart disease, hypertension, stroke, type II diabetes, sleep apnea, 
various cancers, infertility, and overall decreased life expectancy (Haslam & James 2005). 
Obesity and food intake are influenced by a variety of psychological factors such as food choice, 
social interactions, and aesthetics as well as physiological factors such as energy stores, 
endocrine signals, paracrine signals, and neuropeptides. It is debated how each of these factors 
works to cause or cease feeding via peripheral and central control. Peripheral cues are an 
important aspect of food intake control; however, the main focus of this paper will be within the 
central nervous system. 
1.1 The homeostatic pathway of the hypothalamus 
Prior to the 1950s, scientists believed hunger was solely under gastrointestinal control; 
however, the hypothalamus and brainstem gained recognition as major contributors in the role of 
feeding (Kennedy 1953).  Early studies describe the hypothalamus as having a main ‘feeding’ 
center in the lateral hypothalamus and a main ‘satiety’ center in the ventromedial hypothalamus 
(Anand & Brobeck 1951; Teitelbaum & Stellar 1954; Mayer & Thomas 1967), though 
subsequent research has demonstrated that multiple areas of the brain, including areas within the 
hypothalamus play key roles in the regulation of feeding and body weight. One area of the 
hypothalamus shown to play a key role in the regulation of food intake is the arcuate nucleus of 
the hypothalamus (ARC). The ARC has a high number of hormonal and neuropeptide receptors 
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and many of them affect feeding such as opioids, orexins, melanin-concentrating hormone, 
galanin-like peptides, galanin, and many more.  
One important family of ARC neuropeptides that play a key role in regulating feeding are 
the melanocortins. The melanocortins are a family of neuropeptides produced by the 
proopiomelanocortin gene or POMC. Once created the POMC neuropeptide is broken down 
from its preprohormone precursor to physiologically active substances such as 
adrenocorticoptropic hormone (ACTH), α, β, and γ melanocyte-stimulating hormone (MSH), and 
β-endorphin (Mountjoy et al 1992; Palkovits et al 1987) as seen in Figure 1 (Cone 2006).  
 
 
Figure 1. Breakdown of melanocortin neuropeptides from its original state as a 
preprohormone 
 
 
 
The MSHs are commonly referred to as the melanocortins. α-MSH is considered to be the 
most physiologically relevant melanocyte-stimulating hormone in the CNS because of its 
anorexigenic effects (decreases feeding); however, β and γ-MSH also been shown to have some 
physiological significance (Gantz et al 1999). Intraventricular injection of α-MSH is known to 
cause decreased food intake, increase energy expenditure, and chronically can cause cachexia, or 
POMC preprohormone is broken down from its preprohormone precursor to N-terminal, 
adrenocorticoptropic hormone (ACTH), and β-lipotropin (LPH) which are then broken down to 
create α, β, and γ melanocyte-stimulating hormone (MSH), corticotrophin-like intermediate 
peptide (CLIP), γ-LPH, and β-endorphin (Cone 2006). 
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extreme weight loss and malnourishment (Panskepp et al 1976; Fan et al 1997). A second set of 
neurons in the hypothalamus expresses agouti-related protein (AgRP), which is an endogenous 
antagonist of melanocortin receptors. AgRP acutely increases food intake, decrease energy 
expenditure, and chronically increases body weight (Fan et al 1997; Huszar et al 1997). AgRP is 
an antagonist to the melanocortins (Corander et al 2011), but can also act as an inverse agonist. 
This suggests that it not only blocks the receptor, but can cause the opposite effect, in this case, 
increased feeding (Haskell-Luevano & Monck 2001; Nijenhuis et al 2001). ACTH is produced in 
response to stress and has implications in grooming and sexual function. It is produced in the 
pituitary gland and mainly affects melanocortin receptors at its site of production as well as the 
adrenal cortex. β-endorphin is an endogenous opioid that has many functions, one being that it 
stimulates food intake through its receptors in the ARC and other places (Appleyard et al 2003).  
There are five known G-protein coupled receptors that react with MSHs, melanocortin-1 
receptor (MC1R) through melanocortin-5 receptor (MC5R) (Griffon et al 1994; Labbe et al 
1994). MC3R and MC4R are the only two receptors present in the central nervous system (CNS) 
and therefore are the main focus of study in neurobiology (Mountjoy et al 1994; Roselli-Rehfuss 
et al 1993; Gantz et al 1993; Chhaklani et al 1996). MC4R is considered the primary MCR 
involved in body weight control because of its high binding affinity with α-MSH and resulting 
strong physiological changes (Gantz et al 1993). MC4R plays a major role in energy homeostasis 
via food consumption control, energy expenditure, changes in sympathetic nervous system 
(SNS) activity. MC4R null mice are hyperphagic, gain weight, and develop insulin-resistance 
induced diabetes (Gantz & Fong 2002; Sutton et al 2006; Huszar et al 1997; Garza et al 2008). 
Melanocortin 4 deficiency is the largest monogenic cause for obesity in humans (Krude et al 
1998; Farooqi et al 2000; Yaswen 1999). Though MC3R plays a role in body weight regulation, 
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the exact role is less clear. MC3R is involved in energy homeostasis via the manipulation of 
energy metabolism, or the fat-to-mass ratio. MC3R null mice do not increase food intake, but 
have a higher fat to mass body ratio than its wild-type counterparts. Research suggests this is 
caused by a change in metabolism due in large part to decreases in locomotor activity (Sutton et 
al 2006; Butler et al 2000; Chen et al 2000). Although MC3R has binding affinity with α, β and, 
γ-MSH, it has a lack of unique agonists/antagonists that exclusively bind to the MC3R which has 
made studying its effects difficult. Many still question the importance of MC3R due to 
confounding research (Lee et al 2008; Fan et al 1997). Recent papers, however, show that MC3R 
does in fact effect feeding, but the mechanism is still unknown (Marks et al 2006; Irani et al 
2011). 
Among the many neuronal subtypes in the ARC, two populations of neurons have been 
shown to play an important role in feeding, the first expressing proopiomelanocortin (POMC) 
and a second set of neurons expressing agouti-related peptide (AgRP) and neuropeptide Y 
(NPY). POMC neurons are potent anorexigenic stimulators while AgRP/NPY neurons are potent 
orexigenic stimulators (increase feeding) (Huzsar et al 1997; Fan et al 1997; Bulter et al 2000). 
Recent DREADD and optogenetic technologies have shown that stimulation of POMC neurons 
decreases food intake and body weight in the presence of only melanocortins and no other 
neuropeptide (Aponte et al 2011). Stimulation of the AgRP/NPY neurons acutely and 
dramatically increases food intake, decrease energy expenditure, and chronically increases body 
weight (Aponte et al 2011). Inhibition of AgRP neurons decreases food intake to below baseline 
standards independent of melanocortin stimulation suggesting AgRP is both ‘necessary and 
sufficient’ for feeding behavior (Krashes et al 2011). POMC and AgRP/NPY neurons share 
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many of the same projections as seen in Figure 2 (Cone 2005). This allows these two opposing 
systems to have control on each other.  
 
Figure 2. Projections of POMC and AgRP neurons throughout the rat brain 
 
 
 
Other hormones that interact with the homeostatic pathways to affect feeding and body 
weight are leptin, insulin, and ghrelin. Leptin is a hormone that is largely made by white adipose 
tissue, and it decreases with hunger, increases with satiety, and inhibits feeding via receptors in 
the ARC (Frederich et al 1995; Maffei et al 1995; Zhang et al 1994; Halaas et al 1995; Elmquist 
et al 1998). Insulin increases with blood glucose levels (Polonsky et al 1988), and causes 
hypophagia and weight loss within the CNS (McGowen et al 1992). Another peptide, ghrelin, 
has orexigenic effects by activating AgRP/NPY neurons in the ARC while suppressing POMC 
neural activity causing an overall increase in feeding and body weight (Seoane et al 2003; 
POMC and AgRP neurons both project to the central nucleus of the amygdala, bed nucleus of 
the stria terminalis, lateral hypothalamus, and paraventricular nucleus of the hypothalamus. 
POMC exclusively projects to the dorsal motor nucleus of the vagus, reticular nucleus, nucleus 
tractus solitaries, and lateral paracrachial nucleus (Cone 2005). 
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Cowley et al 2003; Wren 2000). Although, there is no one cause for food consumption, the 
melanocortins and the peptides that affect them play a vital role in feeding. Furthermore, more 
recent studies focus on how the ‘reward pathway’ contributes to rewarding aspects of feeding. 
1.2 Mesolimbic dopamine pathway 
There are certain areas within the brain that aid in motivation, learning, and pleasure. 
These circuits are responsible for the hedonics, or pleasure, of food intake without affecting the 
biological necessity of it. This occurs by changing the body’s response to salient environmental 
stimuli causing food intake during a time of food availability rather than for energy needs. This 
can result in a pleasurable experience. Evolutionarily speaking, without these pathways, animals 
with full energy stores would not always eat when food was available, and once food availability 
ran out, starvation could occur. One of the major hormones responsible for hedonic feeding is 
dopamine. One of its many neuronal projections extends from the ventral tegmental area (VTA) 
to the nucleus accumbens (NAc) and in combination with other projections is known as the 
mesolimbic dopamine (DA) system.  
Researchers unknowingly began looking into this ‘reward’ area of brain while researching 
the cause for drug addiction. Drugs of abuse hijack these pathways which can be evolutionarily 
assumed to be useful when finding food or water. Dr. Roy A. Wise was one of the original 
researchers to focus his attention on the addiction phenomena. It was found that dopamine was 
important for brain self-stimulation (Yeomans 1979), and that positive drug self-administration 
regions of the midbrain overlapped with areas with a high density of dopaminergic cell bodies, 
specifically in the VTA and substantia nigra (Corbett & Wise 1980; Bozarth & Wise 1981; Wise 
1982). At this time dopamine was the neurotransmitter believed to cause these addictions (Wise 
1982). Studies confirmed in rats and humans that dopamine related to addiction and drugs of 
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abuse are found in the mesolimbic DA pathway, specifically from the VTA projecting to the 
ventral striatum, which includes the NAc (Di Chiara & Imperato 1988; Koob 1992; McBride et 
al 1999; Volkow et al 2004). Although, the VTA and NAc are often focused on, there are many 
other areas involved in this system; these include the dorsal striatum (caudate putamen- CPu), 
prefrontal cortex, and the amygdala. Research shows that it is the neurotransmitter dopamine in 
the NAc that causes the behavior to seek the drug, or the reward, and that without dopamine, its 
receptor, or its neurons, the self-administration or seeking behavior disappears (Ikemoto et al 
1997; Roberts & Koob 1982). The result of increased dopamine levels from drugs of abuse 
typically decreases dopamine-2 (D2) receptors (Volkow et al 2002). It is assumed that this 
occurs as a reaction to an overabundance of dopamine; however, at this point it then requires 
more dopamine, i.e. more drugs of abuse, to receive the same dopaminergic effect of a smaller 
number of receptors.  This phenomenon is thought to play a role in tolerance and addiction. This 
is shown in self-administration studies where mice progressively increase the amount of cocaine 
with similar resulting dopamine output (Ahmed et al 2002). The mechanisms by which dopamine 
is increased depends of the specific drug of abuse (Ritz et al 1987).  
Dopamine is often considered the major component of the mesolimbic DA system, 
however, other transmitters play key roles in regulating the overall activity of this system.  
Glutamate plays an important role in these pathways with afferent projections from areas such as 
the hippocampus (O’Donnell & Grace 1995). GABA and endogenous opioids also affect the 
activity of this system and compose a feedback loop within the reward pathway (Trigo et al 
2010). In addition, acetylcholine (ACh), which has interneurons in the NAc and various other 
projections throughout the system, is also an important regulator of the mesolimbic DA pathways 
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(Mark et al 2011). The mesolimbic dopamine pathway has been studied for decades and is still 
not completely understood. 
1.3 Mesolimbic Dopamine System and Feeding 
Dopamine is an important neurotransmitter with a wide range of physiological functions 
including motivation, reward, and reinforcement, learning and memory, and motor control. 
Conditions associated with abnormal dopamine show changes in feeding and body weight. For 
example, dopamine-deficient (DD) mice are hypoactive, aphagic, and adipsic and will starve to 
death without help (Zhou & Palmiter 1996). Certain atypical antipsychotics are dopamine-2 (D2) 
receptor antagonists and are known to cause increased weight gain (Baptista et al 1990). D2 
density has also been shown to be inversely proportional to the weight of obese patients 
suggesting a potential role of D2 receptors in development of obesity (Wang et al 2002). One 
study shows clozapine, a partial dopamine receptor antagonist, increases food intake in rats, and 
a D2 receptor agonist reverses it (Kaur & Kulkarni 2002). Parkinsons disease is characterized by 
dopamine cell death in the substantia nigra and its patients have lower body weight than their 
healthy counterparts (Beyer et al 1995). Patients that are given more levodopa treatments, a 
dopamine precursor, have a larger amount of weight loss suggesting the medication may be 
responsible (Bachmann et al 2009). 
As humans, we have the tendency to ‘finish our plate’ of food past the necessary need for 
energy balance (Jansen et al 2003; Weingarten 1983). This alone suggests that some other 
control systems other than basic energy needs are involved in feeding. Despite the important role 
of the mesolimbic DA pathways in drugs of abuse, it is thought that these pathways were 
originally designed to respond to naturally rewarding substances.  Food and water increase 
dopamine in the NAc and VTA similar to, but less than, drugs of abuse. This suggests that it is 
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the overall reward that dopamine triggers, and is not specific to drugs (Hernandez & Hoebel 
1988; Yoshida et al 1992). It has been shown that ‘addicted’ animals prefer highly-intense sugar 
over cocaine suggesting that it is possible that food has the potency to be just as addicting as any 
drug of abuse (Lenoir et al 2007). The mechanism for overeating shows similarities to drugs of 
abuse. Obese patients have decreased D2 receptors similar to the decrease in drug addicts (Wang 
et al 2001). In addition, patients who have undergone gastric bypass surgery have upregulated 
D2 receptors, in theory, to try to restore the dopamine levels to previous pre-surgery ‘reward’ 
levels (Steele et al 2010). Similar findings have been shown in obese rats that are then placed on 
a restricted feeding diet resulting in weight loss (Hamdi et al 1992). Rats on high fat diets are 
less likely to experience ‘reward’ due to decreased self-stimulation, and presumably decreased 
D2 receptors. When the D2 receptors are knocked down, feeding dramatically increases 
supporting the theory that dopamine is what is responsible for giving the ‘rewarding’ feeling. It 
is also possible that without these receptors animals will consume drugs or food to try to receive 
the same dopamine stimulation. In evolution theory, these reward pathways were likely put in 
place for species necessities such as food, water, and reproduction; however, drugs of abuse use 
these pathways to cause their own rewarding effects. Although the reward pathway can 
independently affect feeding, its interactions with other pathways are just as important. 
1.4 Reward and the dorsal striatum 
Although the ventral striatum/NAc gets a lot of attention in the mesolimbic DA pathway, 
the dorsal striatum is a key target for DA output as well. The dorsal striatum which is composed 
of the caudate putamen (CPu) is another key area of interest. Its inputs include the cortex, 
thalamus, and the mesolimbic DA neurons which are similar areas to the ventral striatum 
pathways (VTA to NAc). The NAc has dopaminergic innervations via the VTA whereas the CPu 
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has domaminergic innervations via the substantia nigra. These DA neurons have been 
characteristically associated with motor function and their deficiency with the neuromuscular 
disorder Parkinsons Disease (PD) (Chase et al 1996). PD patients have symptoms that include 
hypophagia; however, this is attributed to the associated dysphagia and depression. The CPu’s 
effects on reward were shown as far back as the 80s (Hikosaka et al 1989). Research also 
associates the CPu with learning, which is an important component of reward (Jog et al 1999; 
Packard & White 1990).  
While the CPu has known effects in drugs, learning, and PD, recent research has indicated 
importance in feeding. Szczypka et al restored DA in dopamine deficient (DD)-mice only in the 
CPu. This resulted in mice regaining the motivation to eat and ability to maintain an adequate 
sustainable body weight which is not possible in DD-mice (Szczypka et al 2001). In addition, it 
has been shown that dopamine increases in relation to drinking in rats in the NAc as well as the 
CPu (Young et al 1992). This suggests that it is possible that motivation and learning, which are 
components of addiction and rewarding behavior, to eat or drink is not solely contained within 
the ventral striatum and its efferent projections from the VTA. The ‘reward’ circuits may lie 
within the ventral as well as dorsal striatum. This also suggests that the hypophagia associated 
with Parkinsons may be due to the dopamine or melanocortin neuronal changes in the dorsal 
striatum. 
1.5 Mesolimbic and homeostatic feeding pathway interactions 
While most research has focused on the role of homeostatic or hedonic pathways of food 
intake control independent of each other, it is clear that there are important interactions between 
these pathways.  Although this is thought of as a new area of study, researchers have been 
investigating this connection for decades. It has been shown that animals will lever-press for 
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heroine injections into the hypothalamus, a role traditionally thought of in the mesolimbic DA 
pathway (Gerber et al 1981). In addition, excitation of the lateral hypothalamus via the medial 
forebrain bundle causes the same dopamine release in the NAc independent of the VTA 
(Hernandez & Hoebel 1988; 1988). By 1992 evidence of a direct link between the NAc shell and 
the lateral hypothalamus was well documented (Heimer et al 1991; Zahm & Brog 1992), and it 
was known that the NAc has role in feeding behavior (Salamone 1994).  
The mechanism of how these two pathways interact and how they affect food intake is still 
developing. Rada et al found glutamate levels in the lateral hypothalamus and the NAc changed 
in response to food intake suggesting not only do these areas share pathways, but that they also 
aid in the control of feeding (Rada et al 1997). Also, NAc-induced feeding could be attenuated 
with GABA agonist injections into the lateral hypothalamus (Maldonado-Irizarry et al 1995). In 
addition to the NAc the hypothalamus has been shown to have connections to the VTA. 
Retrograde tracing injected into the lateral hypothalamus shows strong afferents in the VTA, 
NAc shell, and many other areas (Duva et al 2005). Orexin, an orexigenic neuropeptide, has been 
shown to have projections from the lateral hypothalamus to the VTA (Fadel & Deutch 2002). 
Also, orexin injected into the VTA causes firing, and orexin projections to the VTA are required 
for morphine-related conditioned place preference (Korotkova et al 2003; Narita et al 2006). 
Recent studies have shown that orexin signaling in the VTA is required for opioid-induced food 
intake in the NAc suggesting not only a connection between the lateral hypothalamus and the 
VTA, but a possible relationship to rewarding food intake (Zheng et al 2007). In addition to 
orexin, melanin-concentrating hormone (MCH), another orexigenic neuropeptide, also has 
projections from the lateral hypothalamus to the mesolimbic DA pathway (Bittencourt et al 
1992) with many receptors in the VTA and NAc specifically (Hervieu et al 2000). Smith et al 
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showed that MCH-1 receptor knockout mice, characterized by hyperactivity and hypophagia, 
have increased dopamine in the VTA as well as the NAc further suggesting a functional 
association between these two areas (Smith et al 2005). 
In addition to the neuronal connection between the VTA, NAc, and lateral hypothalamus, 
dopamine neurons in the VTA have receptors for important feeding relevant hormones similar to 
the ARC. Leptin, insulin, and ghrelin not only affect feeding via the homeostatic pathways, but 
they also have effects on dopamine within the mesolimbic DA system to affect feeding. Leptin 
when injected in the ventricles decreases feeding-evoked dopamine release in the NAc (Krugel et 
al 2003). Insulin receptors have also been found in the VTA dopaminergic neurons, (Pardini et al 
2006; Figlewicz et al 2003) and intraventricular insulin was shown to reduce the self-stimulation 
of sucrose (Figlewicz et al 2006). Ghrelin increases dopamine firing in the VTA and decreases 
inhibitory firing and as a result causes food intake (Abizaid et al 2006; Naleid et al 2005). Figure 
3 created by RD Palmiter shows the different hormones and neuropeptides that have been shown 
to affect dopaminergic neurons in the VTA (Palmiter 2001). 
 
Figure 3. Neuropeptides that affect dopamine neurons 
 GABA, leptin, and insulin have been shown to have inhibitory receptors on DA neurons in the 
VTA, while ghrelin, orexin, and glutamate have been shown to have excitatory receptors in the 
VTA (Palmiter 2001). 
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1.6 Mesolimbic dopamine pathway and melanocortin interactions 
In addition to leptin’s, insulin’s, and ghrelin’s interaction with dopaminergic pathways, 
there is also evidence indicating melanocortin involvement within the VTA and the mesolimbic 
DA system.  MC4R mRNA has been found in the VTA, NAc, and CPu, and the MC3R has been 
found extensively in the VTA (Kishi et al 2003; Liu et al 2003; Rosseli-Rehfuss et al 1993). α-
MSH injections in the VTA have been shown to increase dopamine turnover and grooming in 
rats, a typically melanocortin characterization, via the MC4R (Klusa et al 1998; Lindblom et al 
2001). In addition, γ1-MSH injections into the VTA increase dopamine and its metabolites in the 
NAc (Jansone et al 2004). In 1986, it was shown that α-MSH injected into the ventricles or 
substantia nigra causes changes in dopamine in the caudate putamen (Torre & Celis 1986). Davis 
et al showed that centrally administered AgRP, a melanocortin antagonist, increased dopamine 
firing in the midbrain with associated dopamine turnover in the prefrontal cortex, a known 
projection site of mesolimbic DA neurons (Davis et al 2011).  
Many studies looking at drugs of abuse have also linked melanocortins with the 
mesolimbic DA pathway. Alvaro et al showed that morphine down-regulated MC4R in the NAc 
as well as the CPu (1996). An exogenous melanocortin receptor agonist was shown to cause an 
increase in rewarding effects of amphetamines in the lateral hypothalamus (Cabeza de Vaca et al 
2002). Similarly, an exogenous melanocortin receptor antagonist caused a decreased in 
rewarding effects of cocaine in the NAc (Hsu et al 2005, 2009). Here, the term ‘rewarding 
effects’ refers to the perceived reward received from drugs of abuse and the reinforcing 
motivation to seek said drug. In addition, POMC mRNA was shown to decrease in response to 
morphine (Bronstein et al 1990). This building research shows that the melanocortins interact 
with mesolimbic DA system to affect responses to various drugs of abuse. 
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It seems clear that the melanocortins interact with the mesolimbic DA pathway for some 
behaviors; however, there is little research referring to this interaction and its direct effects on 
feeding. Xenakis and Sclafani showed that a dopamine receptor antagonist suppressed sucrose 
preference (1981). In addition, melanocortin agonists or NPY antagonists can inhibit opioid 
induced feeding in the NAc (Zheng et al 2010). These findings suggest that melanocortins and 
AgRP/NPY have projections as well as possible feeding related interactions with the NAc. 
Figure 4 shows the theorized mechanism for how the homeostatic pathway interacts with the 
reward pathway (Palmiter 2007).  In addition, recent studies have shown that melanocortin 
agonists injected directly into the VTA cause a decrease in food intake (Roseberry, personal 
communication), however, more information is required to fully understand the role 
melanocortins play in the mesolimbic DA system to affect feeding. 
1.7 Research Goals 
I will create short-hairpin RNAs (shRNAs) that target MC3R and MC4R separately. These 
shRNAs will be used in in vitro co-transfections with their target receptors to examine 
knockdown efficiencies of each shRNA.  
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Figure 4. A sample of the known relationships between the homeostatic and reward 
pathways 
 
 
 
 
2 METHODS/EXPERIMENTAL PROTOCOL 
2.1 Creation of shRNA targeting the MC3R and MC4R 
Three 24 base pair short hairpin RNAs (shRNAs) were designed to target the MC3R and 
three to target the MC4R  The shRNAs were created using previously developed methods 
(Hommel et al 2003) and BLASTed to ensure specificity. The sequences of each shRNA can be 
seen in Table 1.  
 
 
Leptin and insulin act on the ARC on POMC/CART and AgRP/NPY neurons to decrease 
feeding while ghrelin acts on these areas to increase feeding in the homeostatic pathway. 
POMC/CART and AgRP/NPY neurons both have projections to many similar locations 
including the paraventricular nucleus and the lateral hypothalamus. Orexin neurons project from 
the lateral hypothalamus to the VTA of the reward pathway. The reward pathway consists of DA 
and GABA projections to the NAc. Leptin, insulin, and ghrelin also can act in the VTA (Palmiter 
2007). 
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Table 1.  Targeted mRNA sequences used to create pAAV short-hairpins 
 
  mRNA sequence 
MC3R   
 sh1 TCCCTGACCTTGGAGGACCAATTC 
 sh2 TGCGGCGTGATGTTCATCGTCTAC 
 sh3 ACACGGCGCACTTCAACACCTACC 
MC4R   
 sh1 TCATAAGCCTGTTGGAGAACATTC 
 sh2 GCAGTGGACAGGTATTTCACTATC 
 sh3 CTACATCTCTTGTCCTCAGAATCC 
CONTROL   
  CGGAATTTAGAAACCCGGCTCCAA 
  
 
The control mRNA sequence was created and tested previously and has no known target 
(Hommel et al 2003). Effective shRNAs were created by using a 10 nucleotide hairpin loop 
(CTTCCTGTCA) to join the antisense shRNA to the corresponding sense strand sequence as 
shown in Figure 5. The shRNAs were cloned into a pAAV vector using standard methods to be 
used for future creation of adeno-associated viruses (AAVs). The AAV shRNA constructs will 
express the shRNAs under control of the mU6 promoter, and also contain GFP under the control 
of the CMV promoter to allow for high level expression of both the shRNA and the marker GFP 
as seen in Figure 6. 
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Figure 6. Design of AAV shRNAs 
 
 
2.2 ptdTomato-MC3/4R creation  
Gene fusion constructs were created containing the MC3R or MC4R cDNA fused to the C-
terminus of the tdTomato fluorescent protein in the ptdTomato-C1 vector (Clontech 
Laboratories) using EcoRI and XbaI restriction enzymes and standard molecular biology 
techniques. These fusion constructs will be used for in vitro studies to test shRNA ability to 
suppress tdTomatoMC3/4R. The MC4R was received as a generous gift from Dr. Xin-Yun Lu, 
University of Texas Health Science Center at San Antonio, and the MC3R was synthesized de 
novo by GenScript. The MC3/4R portion of the tdTomatoMC3/4R fusion constructs are not in 
frame so no mature MC3/4R protein is attached to the C-terminus of the functional tdTomato 
protein; however, there is full mRNA expression which allows for targeting of the tdTomato 
MC3/4 R mRNA by the shRNAs.  
The sense strand is the 24 bp target RNA sequence followed by a hairpin loop, the antisense 
strand, followed by a terminating poly T tail. 
Figure 5. Schematic of short-hairpin creation used in RNAi 
Image shows that GFP is controlled by a CMV promoter while the shRNA is controlled by a 
mU6 promoter 
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2.3 shRNA testing in vitro 
The pAAv-shRNA constructs, as described in 2.1, were co-transfected with the 
tdTomatoMC3/4R fusion constructs, as described in 2.2, into HEK-293 cells to determine the 
most effective shRNA to be used for in vivo experimentation. The pAAV-shRNA (5 μg) and 
ptdTomatoMC3/4R (1 μg) DNAs were co-transfected into HEK-293 cells using standard 
calcium-phosphate methods (Roseberry et al 2001). Each shRNA in vitro experiment was  
Table 2. Experimental co-tranfections into HEK-293 cells 
 
 
ptdTomatoMC3R + pAAV-MC3Rsh1 ptdTomatoMC3R + pAAV-MC4Rsh1 
ptdTomatoMC3R + pAAV-MC3Rsh2 ptdTomatoMC3R + pAAV-MC4Rsh2 
ptdTomatoMC3R + pAAV-MC3Rsh3 ptdTomatoMC3R + pAAV-MC4Rsh3 
ptdTomatoMC3R + pAAV-shControl ptdTomatoMC3R + pAAV 
ptdTomatoMC3R + pAAV ptdTomatoMC3R + pAAV-MC3Rsh2 
ptdTomato-MC4R + pAAV-MC4Rsh1 ptdTomatoMC4R + pAAV-MC3Rsh1 
ptdTomato-MC4R + pAAV-MC4Rsh2 ptdTomatoMC4R + pAAV-MC3Rsh2 
ptdTomato-MC4R + pAAV-MC4Rsh3 ptdTomatoMC4R + pAAV-MC3Rsh3 
ptdTomato-MC4R + pAAV-shControl ptdTomatoMC4R + pAAV 
ptdTomato-MC4R + pAAV ptdTomatoMC4R + pAAV-MC4Rsh2 
 
performed 3-4 times and included an empty pAAV and a pAAV control shRNA as internal 
controls. Cells were plated to polylysine covered cover-slips one day post-transfection and were 
then fixed with methanol/acetone and mounted to slides three days post-transfection.  
 As seen in Table 2, specificity was tested by completing co-transfections with 
MC3RshRNAs with tdTomatoMC4R and MC4RshRNAs with the tdTomatoMC4R. These 
experiments also had an empty pAAV vector as a negative control and a receptor-specific short-
hairpin as a positive control. 
The pAAV-shRNA co-transfected with its target receptor, as seen on the left, are used to test 
knockdown effectiveness, while the pAAV-shRNA co-transfected with a control target, as seen 
on the right, are used to test knockdown specificity of the shRNA.  
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2.4 Data Analysis and Statistics 
Slides containing the transfected cells were viewed using a Nikon E800 upright microscope. 
Slides were randomly sampled and approximately ten images were taken per transfection. Image 
acquisition parameters were the same for all treatments in each individual experiment. Images 
were quantified using ImageJ software (National Institute of Health, Bethesda, MD). Positive 
cells were selected using brightness thresholds and cell counter functions, and all measurements 
were confirmed by experimenter. Paired t-tests were used to compare the number of GFP and 
tdTomato positive cells for each treatment. One-way ANOVA with Holm-Sidak post-hoc tests 
were used to compare the level of tdTomato knockdown observed for each pAAV construct.  
3 RESULTS 
Three pAAV-shRNAs were created targeting the MC3R or MC4R, and each shRNA was 
tested in vitro for its effectiveness in knocking down MC3R or MC4R. The knockdown was 
measured by comparing the number of cells expressing tdTomato to the number of cells 
expressing GFP, which is expressed by pAAV, and is used to mark all transfected cells. The 
MC3/4Rs are fused to the C-terminus of the tdTomato and will produce one mRNA that will be 
targeted by the shRNAs. In a successful knockdown, the shRNAs, co-expressed with GFP, will 
knockdown the tdTomatoMC3/4R fusion reducing tdTomato fluorescence. In an unsuccessful 
knockdown, both GFP and tdTomato fluorescence will be present. As mentioned previously, the 
MC3/4R is not in frame with the tdTomato, and no functional receptor protein will be created; 
however, these experiments will remain unaffected because the tdTomato fluorescent protein 
will still be expressed. In each experiment, an empty pAAV vector and a scrambled control 
short-hairpin were co-tranfected with each tdTomato-receptor as negative controls.  
20 
Initially, the MC3R shRNAs were tested (Figure 7-9). The three shRNAs targeting MC3R 
significantly decreased tdTomatoMC3R expression (Figure 7-9) to varying degrees.  MC3Rsh2 
had the greatest tdTomato knockdown with 85.5% followed by MC3Rsh3 with 78.9% and 
MC3Rsh1 with 70.8% (Figure 9). Finally, as expected, the control shRNA had no effect on 
tdTomatoMC3R expression (Figure 7-9). 
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Figure 7. Sample images showing effectiveness of the MC3R shRNAs on tdTomatoMC3R 
expression 
 
 
Green cells indicate GFP expressed by the pAAV-shRNA, and red cells indicate 
tdTomatoMC3R expression. A decrease in the number of red cells as compared to green cells is 
indicative of the ability of the shRNA to block expression of the tdTomato-MC3R. 
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Figure 8. MC3R shRNAs decrease expression of tdTomatoMC3R in HEK-293 cells 
 
 
 
 
Figure 9. Extent of knockdown of the tdTomatoMC3R by the MC3R shRNAs 
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Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following 
co-transfection of the shRNAs with the tdTomatoMC3R. ‘Empty’ refers to pAAV vector with 
no shRNA.  *p < 0.05; n=4. 
All three shRNAs decreased expression of tdTomatoMC3R compared to empty pAAV and 
shControl.  *p < 0.001 compared to both empty pAAV and shControl; n=4. 
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Next, MC4R shRNAs were tested to investigate their ability to block expression of the 
tdTomatoMC4R As with the MC3R, all MC4R shRNAs decreased tdTomato expression to 
varying degrees (Figure 10-12). MC4Rsh3 was the most effective (90.4% knockdown) followed 
by MC4Rsh2 (88.6% knockdown) and MC4Rsh1 (73.7% knockdown). Finally, similar to 
MC3R, the control shRNA had no effect on expression of the tdTomatoMC4R protein (Figure 
10-12). 
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Figure 10. Sample images showing effectiveness of the MC4R shRNAs on tdTomatoMC4R 
expression 
 
 
Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato 
expression. A decrease in the number of red cells as compared to the green cells is indicative of 
the ability of the shRNA to block expression of the tdTomatoMC4R. 
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Figure 11. MC4R shRNAs decrease expression of tdTomatoMC4R in HEK-293 cells 
 
 
 
 
Figure 12. Extent of knockdown of the tdTomatoMC4R by the MC4R shRNAs 
 
 
* 
* * 
0 
50 
100 
150 
200 
250 
300 
350 
400 
Empty shControl MC4Rsh1 MC4Rsh2 MC4Rsh3 
To
ta
l n
u
m
b
e
r 
o
f 
ce
lls
 
GFP 
tdTomato 
* 
* * 
-20 
0 
20 
40 
60 
80 
100 
Empty shControl MC4Rsh1 MC4Rsh2 MC4Rsh3 
%
  t
d
To
m
at
o
 K
n
o
ck
d
o
w
n
 
Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following 
co-transfection of the shRNAs with the tdTomatoMC4R. ‘Empty’ refers to pAAV vector with 
no shRNA.  * p< 0.05; n=3. 
 
All three shRNAs decreased expression of tdTomatoMC4R compared to empty pAAV and 
shControl.  * p< 0.001 compared to both empty pAAV and shControl; n=3. 
26 
Experiments were also performed to test the specificity of the shRNAs. In these experiments 
the ability of the MC3R shRNAs to affect expression of the tdTomatoMC4R was tested, as was 
the ability of the MC4R shRNAs to affect expression of the tdTomatoMC3R. As shown by 
Figures 13-16, none of the shRNAs affected expression of the non-targeted receptor. This 
suggests that all six of the shRNAs are specific to their own receptor. Overall, pAAV-MC3Rsh2 
and pAAV-MC4Rsh3 had the greatest tdTomato knockdown, and therefore will be used for 
future in vivo experimentation.  
 
 
Figure 13. Sample images showing no MC3Rsh2 effect on tdTomatoMC4R 
 
Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato 
expression. Images suggest MC3Rsh2 has no knockdown on tdTomatoMC4R and is specific to 
its target receptor, MC3R. 
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Figure 14. MC3R shRNAs do not affect expression of tdTomatoMC4R 
 
 
 
Figure 15. Sample images showing no MC4Rsh3 effect on tdTomatoMC3R 
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Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato 
expression. Images suggest MC4Rsh3 has no knockdown on tdTomatoMC3R and is specific to 
its target receptor, MC4R. 
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Figure 16. MC4R shRNAs do not affect expression of tdTomatoMC3R 
 
 
4 DISCUSSION 
The mesolimbic DA pathway has been shown to have physiological interactions with 
melanocortins (Klusa et al 1998; Alvaro et al 1996; Bronstein et al 1990) as well as melanocortin 
receptor mRNA (Roselli-Rehfuss et al 1993; Kishi et al 2003; Liu et al 2003). This system has 
also been shown to affect feeding via similar mechanisms (Maldonado-Irizarry et al 1995; Wang 
et al 2001; Salamone 1994). Therefore, this pathway acts as a place of interest for better 
understanding melanocortin’s role in feeding behaviors. Previous studies have used a variety of 
techniques (MC4R-null animals, RNAi , cell-specific receptor knockouts) to show that 
melanocortins affect food intake within the hypothalamus (Huszar et al 1997; Balthasar et al 
2005; Garza et al 2008). None of these relatively new techniques, however, have been used to 
understand whether melanocortins affect feeding through the mesolimbic DA pathway.  
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 In these studies, shRNAs targeting the MC3R and MC4R were designed, tested, and 
resulting in varying degrees of successful knockdown. The shRNAs with the highest knockdown 
were pAAV-MC3Rsh2 with 85.5% knockdown (Figure 9) and pAAV-MC4Rsh3 with 90.4% 
knockdown (Figure 12), thus making them the chosen shRNAs for future use in rats in vivo.  
pAAV-MC4Rsh1 is the only short-hairpin created that could be used in rat as well as 
mouse animals models because of a shared coding region, acacggcccatttcaacacctacc, found at 
base pair 167 in the rat. The option of using two different animal models to investigate 
melanocortin’s role in mesolimbic DA pathways could add to the evidence of a conserved 
pathway between species. 
Previous studies have found that the U6 promoter in vitro knockdown was found to be 
~80% (Makinen et al 2006). Another similar study using the U6 promoter to target MC4R in 
vitro found their knockdown ranged from 86 to 94% over three different short-hairpins (Garza et 
al 2008). Therefore, the 85.4 and 90.4% knockdown for MC3R and MC4R respectively seems to 
be an appropriate knockdown level in vitro. Therefore, these shRNAs would be suitable 
candidates for future in vivo testing. The expression of GFP and shRNA is under the control of 
different promoter regions (U6 expresses shRNA; CMV expresses GFP), and effective 
knockdown still occurs as seen in current and previous studies using similar shRNA constructs 
(Hommel et al 2003).  
The shRNA constructs have the potential to answer many questions about the 
connections between melanocortins and the mesolimbic DA pathways, and their roles in a 
number of behaviors including food intake. Based on important roles of both the mesolimbic DA 
system and melanocortins in feeding, a likely first set of experiments would be to examine 
whether MC3R or MC4Rs in the mesolimbic DA system play a role in feeding. MC3R mRNA is 
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found in high levels in the VTA, while MC4R mRNA is found in low levels in the VTA, 
moderate levels in the NAc, and high levels in the CPu (Roselli-Rehfuss et al 1993; Kishi et al 
2003; Liu et al 2003). In addition to the mRNA, it is known that melanocortins have functional 
or physiological effects within the same regions (Klusa et al 1998; Lindblom et al 2001; Jansone 
et al 2004; Alvaro et al 1996; Hsu et al 2005, 2009). Therefore, the VTA, NAc, and CPu are all 
regions of interest that could be examined. While, it is known that dopamine can affect baseline 
feeding, there is evidence to suggest that it affects rewarding feeding as well. Highly palatable 
food causes increased c fos in the VTA (Park & Carr 1998), and inactivation of the NAc causes 
increased preference for high-fat and high-sugar foods (Zhang & Kelley 1997). Thus, normal 
feeding as well as reward-related feeding, such as high fat and high sugar foods, are logical areas 
to be examined. 
In addition to feeding-related studies, melanocortins have also been shown to have drug-
related interactions in the mesolimbic DA system (Alvaro et al 1996; Hsu et al 2005; Bronstein 
et al 1990). Thus, melanocortin shRNAs could also be used to investigate drug-related behaviors, 
such as locomotion, conditioned place preference, and self-administration within the mesolimbic 
DA system.  
 There are multiple methods that could be used to investigate melanocortin effects within 
the mesolimbic DA system; however, RNA interference was the best possible for the questions 
addressed in this study. Genetic knockout animals, in which knockout either occurs throughout 
the brain or in specific cells, are often used to investigate similar questions. It is currently 
unknown, however, which neurons MC3/4Rs are located on, and thus is a disadvantage because 
it cannot be used to target overall regions, i.e. VTA. Another possible method could have been 
agonist or antagonist microinjections. Although this method can target specific regions, it is 
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limited by the number of microinjections allotted to one animal. This limits not only the length 
of the study (acute vs. chronic), but the varying types of behaviors that can be examined within 
one animal. RNA interference is not without downfall however. shRNAs are not likely to create 
100% receptor knockdown. Therefore the full behavioral effects of that receptor cannot be seen.  
In these studies, the ability to target a specific area over a longer period of time was important, 
and thus RNA interference was chosen as the methodology. 
In summary, these highly effective shRNAs can be used to target various regions of the 
mesolimbic DA pathway as well as to examine various behavioral effects within these regions. 
These studies will allow for investigation of melanocortin effects within the mesolimbic DA 
system and for further characterization of melanocortin function in respect to rewarding feeding 
on high-fat foods as well as high-sugar foods.  
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